EP Patent

EP1954316A1 — Methods of treating anxiety disorders

Assigned to Orexigen Therapeutics Inc · Expires 2008-08-13 · 18y expired

What this patent protects

Disclosed are methods of treating an anxiety disorder, e.g., obsessive compulsive disorder, in an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to restore normal monoaminergic tone within t…

USPTO Abstract

Disclosed are methods of treating an anxiety disorder, e.g., obsessive compulsive disorder, in an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to restore normal monoaminergic tone within the synapse.

Drugs covered by this patent

Patent Metadata

Patent number
EP1954316A1
Jurisdiction
EP
Classification
Expires
2008-08-13
Drug substance claim
No
Drug product claim
No
Assignee
Orexigen Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.